6.1 ABO and Rh Blood Group Systems, Antigens, Subgroups, and Weak D Variant

6.1 ABO and Rh Blood Group Systems, Antigens, Subgroups, and Weak D Variant

Biochemistry and Genetics of the ABO System

The ABO blood group system is universally recognized as the most critical system in transfusion medicine. This clinical importance is driven by the consistent presence of naturally occurring, highly immunogenic IgM antibodies in the plasma of individuals who lack the corresponding antigens. Transfusion of ABO-incompatible blood rapidly initiates the classical complement cascade, leading to fatal acute hemolytic transfusion reactions (AHTRs).

The Role of the H Antigen

The foundation of the ABO system is the H antigen. Synthesized by the action of the H gene (FUT1) on chromosome 19, an enzyme called alpha-2-L-fucosyltransferase adds L-fucose to a terminal galactose of a precursor oligosaccharide chain (Type 2 chains on red cells). This newly formed H substance is the mandatory building block for the subsequent addition of A and B sugars.

• Group A: The A gene (chromosome 9) codes for N-acetylgalactosaminyltransferase, which adds N-acetyl-D-galactosamine to the H substance.
• Group B: The B gene codes for D-galactosyltransferase, which adds D-galactose to the H substance.
• Group O: The amorphic O gene produces a non-functional enzyme. Thus, the H substance remains unconverted, giving Group O cells the highest concentration of H antigen.
• Bombay Phenotype (Oh): Individuals inheriting two recessive h alleles (hh) cannot synthesize the H antigen. Consequently, even if they possess functional A or B genes, they cannot express A or B antigens. They type as Group O but will mount a severe hemolytic reaction if given standard Group O blood due to their production of potent, naturally occurring Anti-H. They must receive blood solely from other Bombay individuals.

ABO Forward and Reverse Grouping

Routine ABO typing requires two distinct, complimentary tests:

1. Forward Grouping: Tests patient RBCs with reagent Anti-A and Anti-B to identify surface antigens.
2. Reverse Grouping: Tests patient serum/plasma with reagent A1 and B cells to identify naturally occurring antibodies.

Resolving ABO Discrepancies

A discrepancy occurs when forward and reverse groupings do not align. These fall into four major categories:

• Group I (Antibody-related): Weak or missing antibodies (e.g., newborns, elderly, immunocompromised). Resolution: Incubate reverse typing at room temperature or 4°C to enhance IgM reactivity.
• Group II (Antigen-related): Weak or missing antigens (e.g., subgroups of A, leukemia). Resolution: Wash cells, incubate at room temperature.
• Group III (Protein-related): Rouleaux formation due to elevated globulins (e.g., Multiple Myeloma, Wharton's jelly in cord blood). Resolution: Saline replacement technique or washing cord cells thoroughly.
• Group IV (Miscellaneous): Polyagglutination, cold autoantibodies. Resolution: Warm washing cells, performing auto-absorption.

A Subgroups: A1 vs. A2

The A phenotype is structurally divided into A1 (approx. 80%) and A2 (approx. 20%). A1 cells have densely packed, complex A antigens (around 1 million sites/cell), whereas A2 cells have simpler, sparser A antigens (around 250,000 sites/cell) and retain more unconverted H antigen.

To differentiate them, blood bankers utilize the plant lectin from Dolichos biflorus (Anti-A1 lectin). This reagent heavily agglutinates (4+) A1 red cells but shows no agglutination (0) with A2 cells. Clinical impact: About 1-8% of A2 individuals and up to 35% of A2B individuals produce an allo-anti-A1. If this anti-A1 is reactive at 37°C, the patient must be transfused with Group O or Group A2 red cells to prevent red cell destruction.

The Rh Blood Group System

The Rh system is highly complex, governed by two closely linked genes on chromosome 1: RHD (codes for the D antigen) and RHCE (codes for C, c, E, and e antigens). Unlike ABO antibodies, Rh antibodies are typically IgG, require immune stimulation (transfusion or pregnancy) to form, and do not fix complement efficiently. However, they are a primary cause of extravascular hemolysis in HTRs and severe Hemolytic Disease of the Fetus and Newborn (HDFN).

The D Antigen and Weak D Variant

The D antigen is the most immunogenic blood group antigen outside the ABO system. While most Rh-positive individuals exhibit strong immediate spin reactivity with Anti-D, some show a weakened expression, necessitating a Weak D test (formerly known as Du).

The Weak D phenotype arises from three main mechanisms:

1. Genetic (Quantitative): Mutations in the RHD gene leading to fewer D antigen sites on the membrane.
2. Position Effect (C trans to D): When the C antigen is inherited on the opposite chromosome to D (e.g., Dce/dCe), it sterically hinders the D antigen.
3. Partial D (Mosaic): The D antigen is missing one or more structural epitopes. Crucially, these individuals can form alloanti-D against the missing epitopes if exposed to conventional Rh-positive blood.

Weak D Testing Protocol

If the initial immediate spin Anti-D is negative or less than 2+:

1. Incubation: Incubate the patient's RBCs with Anti-D reagent at 37°C for 15-30 minutes to allow IgG binding.
2. Washing: Wash the cells 3-4 times with saline to remove unbound proteins.
3. AHG Phase: Add Anti-Human Globulin (AHG). Centrifuge and read.
4. Interpretation: If agglutination occurs, the patient is Weak D positive. If no agglutination occurs, Coombs Control Cells (Check Cells) must be added to validate the negative result.

Exam Trap: Blood donors are strictly required to undergo Weak D testing; if positive, their units are labeled Rh-positive. For recipients, routine Weak D testing is not required; immediate-spin D-negative patients are safely transfused with Rh-negative blood to prevent any risk of immunizing a partial D individual.